Lowell Therapeutics
Elaine Liong has 13 years of pharmaceutical industry experience, managing and directing regulatory intelligence and efforts from pre-IND to postmarking regulatory filings. She has written and contributed to 3 pre-INDs, 8 INDs & 1 NDA. Elaine leverages scientific and technical data with the requirements for regulatory approval, identifying and implementing regulatory strategies to innovatively advance drug discovery and development programs.
This person is not in any offices
Lowell Therapeutics
Lowell Therapeutics is developing a breakthrough product and a company that makes a real difference in the lives of critically ill patients in the ICU. The phase 3 primary endpoint for their product, Niyad, will be met by proving it anti-coagulates blood.